C07J 13/007
Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double
Official title: {with double bond in position 17 (20)}
C07J13/007 (Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double) appears on 182 US grants and 176 published applications in this corpus.
Search patents in C07J- Granted patents
- 182
- Published applications
- 176
- Assignees
- 73
- Inventors
- 288
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 4 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 4 | 0 |
| 1982 | 4 | 0 |
| 1983 | 4 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 6 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 6 | 0 |
| 1997 | 3 | 0 |
| 1998 | 7 | 0 |
| 1999 | 9 | 0 |
| 2000 | 9 | 0 |
| 2001 | 3 | 0 |
| 2002 | 5 | 5 |
| 2003 | 2 | 1 |
| 2004 | 2 | 3 |
| 2005 | 3 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 4 |
| 2011 | 2 | 2 |
| 2012 | 0 | 1 |
| 2013 | 2 | 6 |
| 2014 | 0 | 3 |
| 2015 | 2 | 4 |
| 2016 | 4 | 11 |
| 2017 | 5 | 18 |
| 2018 | 10 | 11 |
| 2019 | 12 | 15 |
| 2020 | 7 | 15 |
| 2021 | 10 | 16 |
| 2022 | 7 | 12 |
| 2023 | 6 | 13 |
| 2024 | 9 | 15 |
| 2025 | 3 | 9 |
| 2026 | 2 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Neuroactive steroids and methods of use thereof5 May 2026US 12,617,814 B2Sage Therapeutics, Inc.
- Compositions and methods for treating CNS disorders27 Jan 2026US 12,534,495 B2Sage Therapeutics, Inc.
- Neuroactive steroids, compositions and uses thereof18 Nov 2025US 12,473,327 B2Sage Therapeutics, Inc.
- Cyclin-dependent kinase degraders and methods of use10 Jun 2025US 12,325,725 B2Dana-Farber Cancer Institute, Inc.
- 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof21 Jan 2025US 12,201,640 B2Sage Therapeutics, Inc.
- Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids3 Sep 2026US 2026/0258072 A1Curia Spain, S.A.U.
- Antipseudomonal fusidic acid compounds20 Aug 2026US 2026/0240869 A1The Board of Trustees of the University of Illinois
- Preparation of deoxycholic acid16 Jul 2026US 2026/0200967 A1Crystal Pharma, S.A.U.
- Neuroactive steroids, compositions, and uses thereof30 Apr 2026US 2026/0116911 A1Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof30 Apr 2026US 2026/0116912 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series70US 5,232,917 AUniversity of Southern California · 1993
- 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof59US 9,512,165 B2Sage Therapeutics, Inc. · 2016
- 19-NOR neuroactive steroids and methods of use thereof49US 9,365,611 B2Sage Therapeutics, Inc. · 2016
- Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same48US 9,630,986 B2Sage Therapeutics, Inc. · 2017
- 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof46US 9,725,481 B2Sage Therapeutics, Inc. · 2017